Qureight and Remedy Cell have collaborated to validate the mechanism of action of RC-0315 in the Phase Ib clinical trial for treating idiopathic pulmonary fibrosis (IPF).
The trial’s primary objective is to evaluate the drug’s tolerability and safety.
Go deeper with GlobalData
Exploratory objectives include assessing its impact on the pathology of the disease, which is measured via imaging and biomarker analysis in bronchoalveolar lavage, as well as plasma samples.
RC-0315’s therapeutic effect is credited to its multi-target strategy, providing a regenerative solution for complex fibrotic conditions.
Qureight’s deep learning imaging platform is said to be instrumental in analysing localised lung sections for monitoring the drug’s effects.
An estimated three million people globally are stated to be affected by the progressive interstitial lung disease, IPF.
The disease is characterised by thickening and stiffening of the interstitial lung tissue due to excessive accumulation of collagen.
The drug claims to repair tissue damage in the lung and restore pulmonary function. It is a multifactorial therapy that targets several IPF-associated targets concurrently.
Qureight will integrate its deep-learning technology into the study, providing imaging core lab services.
This encompasses qualification of the site, handling the data, AI image analysis, and quality control.
The drug will be administered directly into a lung segment via bronchoscopy, with Qureight’s AI models analysing lung sub-sections for changes in airways, blood vessels, and fibrosis.
Qureight CEO Dr Muhunthan Thillai said: “Qureight’s AI-driven imaging analysis will allow a more precise assessment of RC-0315’s efficacy, providing the level of detail needed to understand the effects and map this to patient outcomes.
“By focusing on localised changes within sub-sections of the lungs, we can move beyond traditional whole-lung assessments and gain a deeper understanding of the treatment’s impact on airways, fibrosis, and blood vessels.”
